Homology Medicines
A genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
Launch date
Employees
Market cap
AUD4.7m
Enterprise valuation
(AUD121m) (Public information from Mar 2024)
Share price
$47.17 FIXX
Lexington Kentucky (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.7m | 34.0m | 3.2m | 1.2m | 1.0m | 2.0m | - |
| % growth | 62 % | 1157 % | (91 %) | (64 %) | (13 %) | 100 % | - |
| EBITDA | (122m) | (87.6m) | (263m) | (91.0m) | - | - | - |
| % EBITDA margin | (4526 %) | (258 %) | (8206 %) | (7869 %) | - | - | - |
| Profit | (129m) | (95.8m) | (5.0m) | (113m) | (49.5m) | (73.1m) | (104m) |
| % profit margin | (4763 %) | (282 %) | (156 %) | (9772 %) | (4951 %) | (3655 %) | - |
| EV / revenue | 129.5x | 1.5x | -32.0x | 46.3x | 462.5x | 140.8x | - |
| EV / EBITDA | -2.9x | -0.6x | 0.4x | -0.6x | - | - | - |
| R&D budget | 100m | 93.1m | 98.4m | 62.0m | - | - | - |
| R&D % of revenue | 3715 % | 274 % | 3066 % | 5363 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$43.5m | Series A | ||
$83.5m | Series B | ||
| N/A | N/A | IPO | |
$60.0m | Post IPO Equity | ||
* | N/A | Acquisition | |
| Total Funding | AUD196m | ||
